...
首页> 外文期刊>Drugs and aging >Randomized clinical trial of an intravenous hydromorphone titration protocol versus usual care for management of acute pain in older emergency department patients
【24h】

Randomized clinical trial of an intravenous hydromorphone titration protocol versus usual care for management of acute pain in older emergency department patients

机译:静脉氢吗啡酮滴定方案与常规护理治疗老年急诊科患者急性疼痛的随机临床试验

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background and Objectives: Opioid titration is an effective strategy for treating pain; however, titration is generally impractical in the busy emergency department (ED) setting. Our objective was to test a rapid, two-step, hydromorphone titration protocol against usual care in older patients presenting to the ED with acute severe pain. Methods: This was a prospective, randomized clinical trial of patients 65 years of age and older presenting to an adult, urban, academic ED with acute severe pain. The study was registered at http://www.clinicaltrials.gov (NCT01429285). Patients randomized to the hydromorphone titration protocol initially received 0.5 mg intravenous hydromorphone. Patients randomized to usual care received any dose of any intravenous opioid. At 15 min, patients in both groups were asked, 'Do you want more pain medication?' Patients in the hydromorphone titration group who answered 'yes' received a second dose of 0.5 mg intravenous hydromorphone. Patients in the usual care group who answered 'yes' had their ED attending physician notified, who then could administer any (or no) additional medication. The primary efficacy outcome was satisfactory analgesia defined a priori as the patient declining additional analgesia at least once when asked at 15 or 60 min after administration of the initial opioid. Dose was calculated in morphine equivalent units (MEU: 1 mg hydromorphone = 7 mg morphine). The need for naloxone to reverse adverse opioid effects was the primary safety outcome. Results: 83.0 % of 153 patients in the hydromorphone titration group achieved satisfactory analgesia compared with 82.5 % of 166 patients in the usual care group (p = 0.91). Patients in the hydromorphone titration group received lower mean initial doses of opioids at baseline than patients in the usual care group (3.5 MEU vs. 4.7 MEU, respectively; p ≤ 0.001) and lower total opioids through 60 min (5.3 MEU vs. 6.0 MEU; p = 0.03). No patient needed naloxone. Conclusions: Low-dose titration of intravenous hydromorphone in increments of 0.5 mg provides comparable analgesia to usual care with less opioid over 60 min.
机译:背景与目的:阿片类药物滴定是治疗疼痛的有效策略。但是,在繁忙的急诊室(ED)中进行滴定通常是不切实际的。我们的目标是测试针对急诊急诊严重疼痛的老年患者的常规护理快速,两步氢吗啡酮滴定方案。方法:这是一项前瞻性,随机临床试验,研究对象为65岁及以上的成人,城市,学术急诊急症患者。该研究已在http://www.clinicaltrials.gov(NCT01429285)上注册。随机接受氢吗啡酮滴定方案的患者最初接受0.5 mg静脉内氢吗啡酮。随机接受常规护理的患者接受任何剂量的任何静脉阿片类药物。在15分钟时,两组患者都被问到:“您是否需要更多止痛药?”氢吗啡酮滴定组中回答“是”的患者接受了第二剂0.5 mg静脉内氢吗啡酮。常规护理组中回答“是”的患者已通知急诊科主治医师,然后他们可以服用任何(或不服用)其他药物。主要疗效结果是令人满意的镇痛效果,先验定义为患者在给予初始阿片类药物后15或60分钟时要求至少减少一次额外镇痛作用。以吗啡当量单位计算剂量(MEU:1毫克氢吗啡酮= 7毫克吗啡)。主要的安全性结果是需要纳洛酮逆转阿片类药物的不良反应。结果:氢吗啡酮滴定组的153例患者中有83.0%达到了满意的镇痛效果,而常规护理组的166例患者中有82.5%的镇痛效果(p = 0.91)。氢吗啡酮滴定组的患者在基线时接受的阿片类药物的平均初始剂量低于常规护理组的患者(分别为3.5 MEU和4.7 MEU; p≤0.001; p≤0.001),并且在60分钟内总阿片类药物的总剂量较低(5.3 MEU和6.0 MEU) ; p = 0.03)。没有患者需要纳洛酮。结论:以0.5 mg的增量低剂量滴注静脉内氢吗啡酮可提供与常规护理相当的镇痛效果,且在60分钟内阿片类药物较少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号